South African billionaire Stephen Saad’s Aspen stake nears $500 million after turbulent year

South African billionaire Stephen Saad, who founded and runs Aspen Pharmacare, has seen the value of his stake in the pharma company rise by more than $87 million to nearly $500 million, as shares of the Durban-based drugmaker rebound on the Johannesburg Stock Exchange (JSE). 

The recovery follows a turbulent 2025 marked by regulatory setbacks and a costly mRNA contract dispute that erased over $1.2 billion in market value.

Aspen shares rebound after 2025 losses

Data compiled by Shore Africa shows that Saad’s stake gained R1.5 billion ($87.14 million), driven by renewed investor demand for Aspen shares on the local bourse. The rebound marks a partial recovery from steep losses suffered in 2025, when operational and regulatory headwinds weighed heavily on the company.

At the height of the downturn, Aspen’s stock plunged more than 30% in a single session on April 22, 2025, falling to R112 ($6.15), its sharpest one-day drop in over two decades. The selloff followed warnings of a potential R2.77 billion ($147.2 million) earnings hit tied to its mRNA manufacturing dispute. 

Additional pressure came from compliance issues after a key production facility failed to meet standards set by the U.S. Food and Drug Administration, further denting investor confidence. During those hurdles, Saad stood firmly behind the pharma company, buying more shares, which sends a strong message of his belief in the company’s future.

Market recovery lifts valuation to $3.7 billion

Since the start of 2026, Aspen shares have climbed 21.58%, signaling a gradual recovery. The stock opened the year at R113.43 ($6.81) and closed at R139 ($8.34) on April 30, lifting the company’s market capitalization to approximately R62 billion ($3.72 billion).

The rebound reflects stabilizing operations and improving sentiment toward the pharmaceutical manufacturer, which operates in more than 115 countries and remains a key player in Africa’s healthcare supply chain.

Stephen Saad’s stake approaches $500 million

Saad, who founded Aspen in 1997 and serves as CEO, holds a 13.2% stake equivalent to 58.8 million shares. The recent rally has increased the value of his holdings from R6.67 billion ($403.8 million) to R8.17 billion ($490.94 million).

His decision to increase share purchases during the downturn signaled long-term confidence in the business, a move now yielding gains as the stock recovers.

Why this matters

Aspen’s recovery highlights the resilience of Africa’s pharmaceutical sector amid regulatory and operational shocks. As one of the continent’s largest drug manufacturers, its performance has broader implications for healthcare access, local production capacity, and investor confidence in African equities.

The rebound also underscores how strategic insider buying, particularly by founders, can influence market sentiment during periods of volatility, similar to patterns seen in other emerging market firms.

Outlook: cautious optimism amid lingering risks

While the recent rally has restored some investor confidence, Aspen still faces structural challenges, including regulatory compliance, global pricing pressures, and execution risks tied to complex manufacturing agreements.

However, if operational stability continues and demand for specialty pharmaceuticals strengthens, the company could regain momentum toward its previous highs, when shares traded above R230 and its valuation exceeded $5.8 billion in late 2024.